Videos

Chang explains the importance of collaboration between gastroenterologists and allergists in EoE care and praises recent ACG guidelines on disease management.

Maria Hordinsky, MD, spoke at SDPA regarding her talk highlighting a variety of clinical pearls for spotting scarring alopecia early.

In her SDPA interview, Maria Hordinsky, MD, spoke about her session regarding clinical pearls for clinicians seeking to spot alopecia early in patients.

At SDPA 2025, Spizuoco discussed how trichoscopic signs like black dots, yellow dots, and exclamation hairs guide treatment decisions.

This interview segment with Scherer highlights additional takeaways from his SDPA 2025 talk, covering clues for clinicians to identify different interdigital foot infections.

In this interview at SDPA, Scherer provides an overview of foot web space infections, fungal versus bacterial infections, and more.

At SDPA 2025, Cotter highlights clinical patterns in alopecia areata that may respond better, or worse, to JAK inhibition and shares his approach to systemic therapy.

At SDPA 2025, Mangin emphasized the importance of wood lamp use, JAK inhibitors, and phototherapy in managing vitiligo and preventing relapse.

Hope Cook, PA-C, speaks in this interview at SDPA about strategies for clinicians seeking to overcome burnout in their careers.

Silverberg discussers 16-week data for rezpegaldesleukin in atopic dermatitis from the phase 2b REZOLVE-AD trial.

Silverberg discusses the significance of the dupilumab approval in BP and why he thinks it's the most important news in dermatology in 2025 so far.

In this segment of her SDPA interview, Orit Markowitz, MD, highlights several points about dermoscopy, including common issues with identifying benign lesions.

Orit Markowitz, MD, highlighted takeaways from her SDPA presentation on the recognition of benign patterns in dermoscopy.

From uncovering new benefits of semaglutide to targeting hypercortisolism in people with type 2 diabetes, here are 5 key updates from the annual meeting.

Chang reviews key points from her recent paper on the evolving landscape of eosinophilic esophagitis management and lingering knowledge gaps.

This interview at SDPA features Janelle Ball, founder and CEO of BC Educators, who discusses tips related to success with insurance authorizations.

This interview segment at the 2025 SDPA Conference highlights additional insights by Friedman on the management and diagnosis of chronic hand eczema, or CHE.

In an interview conducted at the 2025 SDPA Conference, Friedman provided several insights into management and diagnosis of chronic hand eczema, or CHE.

Verma discussed how recent advances in the field affect clinician management of type 2 diabetes and peripheral artery disease.

Dellon describes what excites him most about EoE recently but points to barriers to optimal care as well as unanswered research questions and clinical needs.

Verma discussed how new data from the STRIDE trial support the role of GLP-1 RAs as protective vascular medications.

Donovan and Feig shared exciting findings and further research from a study evaluating an insulin pump with Control-IQ technology with Dexcom G6 sensor.

From new data for potential IgAN treatments to the use of combination initiation therapy for type 2 diabetes and CKD, here are 5 key updates from the annual meeting.

In this report, Chovatiya highlights lebrikizumab’s evolving role in long-term atopic dermatitis management.

The report highlights lebrikizumab’s potential for sustained disease modification and its evolving role in long-term atopic dermatitis management.

Berry discussed findings from a retrospective, real-world study but emphasized that they should be confirmed in randomized controlled trials.

At SLEEP 2025, Levine discussed how skin biopsy testing for phosphorylated alpha-synuclein may enable early diagnosis and prevention trials for neurodegenerative diseases.

At SLEEP 2025, Sachdeva outlined evolving liability concerns, transparency issues, and steps clinicians can take to safely integrate AI in practice.